14% Revenue and 8% Orders Growth in Q4; Company issues FY25 Guidance
Fourth Quarter Fiscal 2024 Summary
- Net revenue of
$134.3 million , an increase of 13.5 percent from the same period in the prior fiscal year. Net revenue on a constant currency basis was$136.7 million , which represents a 15.6 percent increase versus the same period in the prior fiscal year. - GAAP net income of
$3.4 million , as compared to GAAP net loss of$2.6 million in the same period in the prior fiscal year. Adjusted EBITDA was$10.1 million in the fourth quarter of fiscal 2024 compared to$5.2 million in the same period in the prior fiscal year. - Gross orders of
$95.5 million , increased 7.9 percent from the same period in the prior fiscal year. The book to bill ratio was 1.2 in the fourth quarter of fiscal 2024, compared to a book to bill ratio of 1.4 in the same period in the prior fiscal year.
Fiscal Year 2024 Summary
- Net revenue of
$446.6 million , a decrease of 0.2 percent from the prior fiscal year. Net revenue on a constant currency basis was$447.9 million , which represents an 0.1 percent increase from the prior fiscal year. - GAAP net loss of
$15.5 million , as compared to a GAAP net loss of$9.3 million in the prior fiscal year. Adjusted EBITDA was$19.7 million in fiscal 2024, as compared to adjusted EBITDA of$23.9 million in the prior fiscal year. - Gross orders of
$342.1 million increased 10.0 percent from the same period in the prior fiscal year. The book to bill ratio was 1.5 in fiscal 2024, compared to a book to bill ratio of 1.3 in the prior fiscal year.
Other Recent Operational Highlights
- Achieved record quarterly system shipments with 24 percent increase in systems shipped compared to the same period in the prior fiscal year, resulting in highest revenue quarter in company history.
- Gained approval for the Accuray Precision ® Treatment Planning System (TPS) in
China for use with the Tomo ® C radiation therapy system for the Type B market. - Implemented first installations of the VitalHold™ surface-guided radiation therapy (SGRT) on the Radixact ® System in
Japan . - Gained CE Mark for the Accuray Helix™, a configuration of the Radixact ® Treatment Delivery System designed for
India and other high potential markets where treatment versatility, high throughput and access to radiation therapy treatments are paramount. - Signed agreement with TrueNorth Medical Physics LLC to provide radiation oncology departments with third-party physics, dosimetry and commissioning services.
"Our team finished the year with a solid Q4 performance closing several opportunities that were open from the prior period. We secured new product approvals and significant customer wins, and initiated sales in new markets. These achievements and more have enabled us to establish a strong foundation from which to grow our global business in the years ahead," said
Fiscal Fourth Quarter Results
Total net revenue was
Total gross profit in the fourth quarter of fiscal 2024 was
Operating expenses were
Net income was
Gross orders totaled
Cash, cash equivalents, and short-term restricted cash were
Fiscal Year 2024 Highlights
Total net revenue was
Total gross profit was
Operating expenses were
GAAP net loss was
Gross orders totaled
Fiscal Year 2025 Financial Guidance
Accuray's financial guidance is based on current expectations. The following statements are forward-looking and actual results could differ materially depending on market and economic conditions, supply chain disruption, and the factors set forth under "Safe Harbor Statement" below.
The Company is introducing guidance for fiscal year 2025 as follows:
- Total revenue is expected in the range of
$460 million to$470 million . - Adjusted EBITDA is expected in the range of
$27.5 million to$29.5 million .
"Our fourth quarter results reflect a concerted effort by our team to drive improvements in our financial performance while delivering world class products and services to our customers. Our operating results were solid with controlled expenses and strong management of working capital that resulted in a significant decline in inventory and increase in cash. Moving into fiscal 2025, I'm excited about the year ahead and the potential of our new products to help generate revenue and growth in service," said Ali Pervaiz, Chief Financial Officer.
Guidance for Adjusted EBITDA, a non-GAAP financial measures excludes depreciation and amortization, stock-based compensation expense, ERP and ERP related expenditures, interest expense and provision for income taxes. For more information regarding the non-GAAP financial measures discussed in this press release, please see "Use of Non-GAAP Financial Measures" below.
Conference Call Information
Accuray will host a conference call beginning at
U.S. callers: (833) 316-0563- International callers: (412) 317-5747
Individuals interested in listening to the live conference call via the Internet may do so by logging on to the Investor Relations section of Accuray's website, www.accuray.com. There will be a slide presentation accompanying today's event which can also be accessed on the company's Investor Relations page at www.accuray.com.
In addition, a taped replay of the conference call will be available beginning approximately one hour after the call's conclusion and will be available for seven days. The replay number is (877) 344-7529 (
Use of Non-GAAP Financial Measures
Accuray reports its financial results in accordance with generally accepted accounting principles in
Accuray has supplemented its GAAP net income (loss) with a non-GAAP measure of adjusted earnings before interest, taxes, depreciation, amortization, stock-based compensation, ERP and ERP related expenditures and restructuring charges ("adjusted EBITDA"). The calculation of adjusted EBITDA also excludes certain non-recurring, irregular and one-time items. Management believes that this non-GAAP financial measure provides useful supplemental information to management and investors regarding the performance of the company and facilitates a meaningful comparison of results for current periods with previous operating results. A reconciliation of GAAP net income (loss) (the most directly comparable GAAP measure) to non-GAAP adjusted EBITDA is provided in the schedules below.
Accuray has also reported certain operating results on a constant currency basis in order to facilitate period-to-period comparisons of its results without regard to the impact of foreign currency exchange rate fluctuations. Management believes disclosure of non-GAAP constant currency results is helpful to investors because it facilitates period-to-period comparisons of the company's results by increasing the transparency of the underlying performance by excluding the impact of foreign currency exchange rate fluctuations. The GAAP measure most directly comparable to net revenue on a constant currency basis is revenue. Accuray calculates the constant currency amounts by translating local currency amounts in the current period using the same foreign translation rate used in the prior period being compared against rather than the actual exchange rate in effect during the current period.
There are limitations in using these non-GAAP financial measures because they are not prepared in accordance with GAAP and may be different from non-GAAP financial measures used by other companies. These non-GAAP financial measures should not be considered in isolation or as a substitute for GAAP financial measures. Investors and potential investors should consider non-GAAP financial measures only in conjunction with the company's consolidated financial statements prepared in accordance with GAAP.
About Accuray
Accuray Incorporated (Nasdaq: ARAY) is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions that are designed to deliver radiation treatments for even the most complex cases”while making commonly treatable cases even easier”to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to the company's future results of operations, including expectations regarding: total revenue and adjusted EBITDA; the company's ability to invest on innovations and provide customers with products that enables them to elevate cancer care; the company's ability to benefit from advances in long-term growth and profitability drivers; the company's ability to navigate supply chain, logistics, macroeconomic, and foreign exchange challenges; the company's ability to deliver on its strategic growth plan, progressing against long-term strategic goals, and continuing adoption and expand access of its technologies; the company's ability to execute on margin and profitability expansion initiatives; expectations regarding commercial strategy and execution as well as growth opportunities; expectations regarding the company's
Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.
Investor Relations, ICR-Westwicke | Public Relations Director, Accuray |
+1 (443) 450-4191 | +1 (408) 789-4426 |
aman.patel@westwicke.com | bkaplan@accuray.com |
Financial Tables to Follow
Accuray Incorporated | ||||||||||||||||
Three Months Ended | Twelve Months Ended | |||||||||||||||
2024 | 2023 | 2024 | 2023 | |||||||||||||
Net revenue: | ||||||||||||||||
Products | $ | 79,673 | $ | 62,454 | $ | 234,164 | $ | 233,192 | ||||||||
Services | 54,616 | 55,838 | 212,387 | 214,413 | ||||||||||||
Total net revenue | 134,289 | 118,292 | 446,551 | 447,605 | ||||||||||||
Cost of revenue: | ||||||||||||||||
Cost of products | 55,084 | 42,000 | 161,061 | 153,627 | ||||||||||||
Cost of services | 40,753 | 38,614 | 142,569 | 140,018 | ||||||||||||
Total cost of revenue | 95,837 | 80,614 | 303,630 | 293,645 | ||||||||||||
Gross profit | 38,452 | 37,678 | 142,921 | 153,960 | ||||||||||||
Operating expenses: | ||||||||||||||||
Research and development | 9,529 | 14,187 | 49,732 | 57,129 | ||||||||||||
Selling and marketing | 10,696 | 10,667 | 42,619 | 46,178 | ||||||||||||
General and administrative | 11,410 | 13,281 | 50,066 | 48,271 | ||||||||||||
Total operating expenses | 31,635 | 38,135 | 142,417 | 151,578 | ||||||||||||
Income (loss) from operations | 6,817 | (457) | 504 | 2,382 | ||||||||||||
Income on equity investment, net | 810 | 1,612 | 1,838 | 2,572 | ||||||||||||
Other expense, net | (3,769) | (3,131) | (14,162) | (11,742) | ||||||||||||
Income (loss) before provision for income taxes | 3,858 | (1,976) | (11,820) | (6,788) | ||||||||||||
Provision for income taxes | 471 | 580 | 3,725 | 2,492 | ||||||||||||
Net income (loss) | $ | 3,387 | $ | (2,556) | $ | (15,545) | $ | (9,280) | ||||||||
Net income (loss) per share - basic | $ | 0.03 | $ | (0.03) | $ | (0.16) | $ | (0.10) | ||||||||
Net income (loss) per share - diluted | $ | 0.03 | $ | (0.03) | $ | (0.16) | $ | (0.10) | ||||||||
Weighted average common shares used in computing income | ||||||||||||||||
Basic | 99,585 | 95,945 | 98,272 | 94,884 | ||||||||||||
Diluted | 101,028 | 95,945 | 98,272 | 94,884 | ||||||||||||
Accuray Incorporated | ||||||||
2024 | 2023 | |||||||
Assets | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 68,570 | $ | 89,402 | ||||
Restricted cash | 485 | 524 | ||||||
Accounts receivable, net | 92,001 | 74,777 | ||||||
Inventories | 138,324 | 145,150 | ||||||
Prepaid expenses and other current assets | 23,006 | 27,612 | ||||||
Deferred cost of revenue | 850 | 568 | ||||||
Total current assets | 323,236 | 338,033 | ||||||
Property and equipment, net | 24,774 | 20,926 | ||||||
Investment in joint venture | 9,826 | 15,128 | ||||||
Operating lease right-of-use assets | 33,773 | 25,853 | ||||||
Goodwill | 57,672 | 57,681 | ||||||
Intangible assets, net | 59 | 210 | ||||||
Restricted cash | 1,337 | 1,276 | ||||||
Other assets | 17,950 | 20,107 | ||||||
Total assets | $ | 468,627 | $ | 479,214 | ||||
Liabilities and equity | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 50,020 | $ | 33,739 | ||||
Accrued compensation | 17,128 | 23,793 | ||||||
Operating lease liabilities, current | 6,218 | 4,151 | ||||||
Other accrued liabilities | 28,508 | 38,271 | ||||||
Customer advances | 13,988 | 20,777 | ||||||
Deferred revenue | 71,649 | 72,185 | ||||||
Short-term debt | 7,756 | 5,721 | ||||||
Total current liabilities | 195,267 | 198,637 | ||||||
Operating lease liabilities, non-current | 32,373 | 23,602 | ||||||
Long-term other liabilities | 7,389 | 4,675 | ||||||
Deferred revenue | 24,114 | 27,079 | ||||||
Long-term debt | 164,400 | 171,562 | ||||||
Total liabilities | 423,543 | 425,555 | ||||||
Equity: | ||||||||
Common stock | 100 | 97 | ||||||
Additional paid-in capital | 566,887 | 555,276 | ||||||
Accumulated other comprehensive income (loss) | (4,222) | 422 | ||||||
Accumulated deficit | (517,681) | (502,136) | ||||||
Total equity | 45,084 | 53,659 | ||||||
Total liabilities and equity | $ | 468,627 | $ | 479,214 | ||||
Accuray Incorporated | ||||||||||||||||
Three Months Ended | Twelve Months Ended | |||||||||||||||
2024 | 2023 | 2024 | 2023 | |||||||||||||
Gross Orders | $ | 95,472 | $ | 88,447 | $ | 342,148 | $ | 311,094 | ||||||||
63,773 | 67,756 | 210,914 | 182,932 | |||||||||||||
Order Backlog | 487,319 | 510,641 | 487,319 | 510,641 | ||||||||||||
Book to bill ratio (a) | 1.2 | 1.4 | 1.5 | 1.3 | ||||||||||||
(a) Book to bill ratio is defined as gross orders for the period divided by product revenue for the period |
Accuray Incorporated | ||||||||||||||||
Three Months Ended | Twelve Months Ended | |||||||||||||||
2024 | 2023 | 2024 | 2023 | |||||||||||||
GAAP net income (loss) | $ | 3,387 | $ | (2,556) | $ | (15,545) | $ | (9,280) | ||||||||
Depreciation and amortization (a) | 1,507 | 1,097 | 5,905 | 4,527 | ||||||||||||
Stock-based compensation | 2,042 | 2,452 | 9,483 | 10,053 | ||||||||||||
Interest expense, net (b) | 2,686 | 2,735 | 10,676 | 10,340 | ||||||||||||
Provision for income taxes | 471 | 580 | 3,725 | 2,492 | ||||||||||||
Restructuring charges | ” | ” | 2,633 | 2,738 | ||||||||||||
ERP and ERP related expenditures | ” | 900 | 2,815 | 3,078 | ||||||||||||
Adjusted EBITDA | $ | 10,093 | $ | 5,208 | $ | 19,692 | $ | 23,948 | ||||||||
(a) Consists of depreciation, primarily on property and equipment, as well as amortization of intangibles. |
(b) Consists primarily of interest expense associated with outstanding debt. |
Accuray Incorporated | ||||||||
Twelve Months Ending | ||||||||
From | To | |||||||
GAAP net loss | $ | (5,000) | $ | (3,000) | ||||
Depreciation and amortization (a) | 6,500 | 6,500 | ||||||
Stock-based compensation | 10,000 | 10,000 | ||||||
Interest expense, net (b) | 13,000 | 13,000 | ||||||
Provision for income taxes | 3,000 | 3,000 | ||||||
Adjusted EBITDA | $ | 27,500 | $ | 29,500 | ||||
(a) Consists of depreciation, primarily on property and equipment as well, as amortization of intangibles. |
(b) Consists primarily of interest expense associated with outstanding debt. |